US 10,889,646 B2
Use of KIT inhibitors to condition subjects for a hematopoietic stem cell (HSC) transplantation
Punam Malik, Cincinnati, OH (US); and Shanmuganathan Chandrakasan, Cincinnati, OH (US)
Assigned to CHILDREN'S HOSPITAL MEDICAL CENTER, Cincinnati, OH (US)
Appl. No. 15/561,126
Filed by Children's Hospital Medical Center, Cincinnati, OH (US)
PCT Filed Mar. 25, 2016, PCT No. PCT/US2016/024329
§ 371(c)(1), (2) Date Sep. 25, 2017,
PCT Pub. No. WO2016/154588, PCT Pub. Date Sep. 29, 2016.
Claims priority of provisional application 62/138,098, filed on Mar. 25, 2015.
Prior Publication US 2018/0127497 A1, May 10, 2018
Int. Cl. C07K 16/28 (2006.01); C07K 14/71 (2006.01); A61K 35/28 (2015.01); A61K 39/395 (2006.01); A61P 7/06 (2006.01); A61K 39/00 (2006.01); A61K 35/12 (2015.01)
CPC C07K 16/2803 (2013.01) [A61K 35/28 (2013.01); A61K 39/3955 (2013.01); A61P 7/06 (2018.01); C07K 16/2863 (2013.01); A61K 2035/124 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01)] 22 Claims
 
1. A method of conditioning a subject for a hematopoietic stem cell (HSC) transplantation, the method comprising:
administering an effective amount of an inhibitor of a stem cell growth factor receptor (KIT) to a subject who is in need of a HSC transplantation, wherein the subject is hypersensitive to at least one DNA damaging agent;
wherein the subject is free of irradiation treatment or a conditioning regimen comprising a DNA damaging agent before the transplantation of the HSCs.